Occupation or Discipline

Concr Adds Former AstraZeneca and Cancer Research Institute Executives to Advisory Board

2 days ago talkbio0Tagged Advisory Board, AstraZeneca, Biological Science Disciplines, cancer drug development, Cancer Research Institute, DDX11-AS1 gene, executive appointments, Neoplasms, strategic advisory

Concr; AstraZeneca; Cancer Research Institute; advisory board; biotech; oncology; executive appointments; life sciences; strategic advisory; cancer drug development

Ansa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer

3 days ago talkbio0Tagged Ansa, Biotechnology, CBO, CFO, Chief Business Officer, DNA Replication, executive appointment, Geoff Hamilton ; Chief Financial Officer, Leadership, Synthetic Biology

Ansa Biotechnologies; Geoff Hamilton; Chief Financial Officer; Chief Business Officer; CFO; CBO; executive appointment; synthetic biology; DNA synthesis; biotech leadership

Building the Next Generation of Biologics: Inside the Future of Protein Engineering

7 days ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, cryo-EM, generative biology, high-throughput protein production, manufacturability, mini-proteins, molecular glues, next-generation biologics, PROTACs, protein degraders, protein design, Protein Engineering, Structural Biology

next-generation biologics; protein engineering; bispecific antibodies; antibody-drug conjugates (ADCs); protein degraders; PROTACs; molecular glues; mini-proteins; AI in protein design; manufacturability; structural biology; cryo-EM; high-throughput protein production; generative biology

mAbxience and HP Drive the Use of Artificial Intelligence in Biomanufacturing and Biosimilar Development

1 week ago talkbio0Tagged Artificial Intelligence, Biological Factors, biomanufacturing, Biosimilars, development aspects, digital twin, Fresenius, Hereditary pancreatitis, mAbxience, Monoclonal Antibodies, Neural Network Simulation

mAbxience; HP; artificial intelligence; biomanufacturing; biosimilar development; digital twin; monoclonal antibodies; neural network models; biologics; Fresenius

Zentek Appoints Mohammed Jiwan as CEO

2 weeks ago talkbio0Tagged Appointments, CEO, commercialization, Graphene, Jiwan, Mohammed, Nanostructured Materials, Technology, ZenGUARD, Zentek

Zentek; Mohammed Jiwan; CEO appointment; ZenGUARD; nanomaterials; graphene; technology; commercialization

AI Proteins Raises $41.5M Series A to Accelerate AI-Designed De Novo Miniprotein Therapeutics

3 weeks ago talkbio0Tagged AI Proteins, Artificial Intelligence, BioCapital, Biotechnology, de novo miniproteins, Drug Discovery, Religious Missions, Santé Ventures, Series A financing, Synthetic Biology, therapeutic protein

AI Proteins; Series A financing; de novo miniproteins; protein therapeutics; artificial intelligence; drug discovery; Mission BioCapital; Santé Ventures; synthetic biology; biotechnology

Profluent Raises $106M to Accelerate Frontier AI Models for Programmable Biology, Backed by Jeff Bezos

3 weeks ago talkbio0Tagged AI biotech, Altimeter Capital, Bezos Expeditions, Biological Factors, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Funding, Jeff, Profluent, Programmable Biology, Protein Atlas, protein design, Synthetic Biology

Profluent; AI biotech; protein design; programmable biology; Jeff Bezos; Altimeter Capital; $106M funding; Bezos Expeditions; CRISPR; biologics; Protein Atlas; synthetic biology; drug development

Scott Gottlieb, M.D., Joins UnitedHealth Group Board of Directors

3 weeks ago talkbio0Tagged board of directors, Health care facility, Health Policy, innovation, medical breakthroughs, Patient access, Scott Gottlieb, Technology, United States Food and Drug Administration, UnitedHealth Group

Scott Gottlieb; UnitedHealth Group; Board of Directors; FDA; health policy; innovation; patient access; medical breakthroughs; technology in healthcare

Lunit and Labcorp Partner to Transform Tumor Microenvironment Analysis with AI-Powered Digital Pathology

4 weeks ago talkbio0Tagged Artificial Intelligence, Biological Markers, digital pathology, Discover, Labcorp, Lunit, MET exon 14 skipping mutation, Non-Small Cell Lung Carcinoma, precision oncology, spatial profiling, Tumor Microenvironment

Lunit; Labcorp; artificial intelligence; digital pathology; tumor microenvironment; spatial profiling; biomarker discovery; precision oncology; non-small cell lung cancer (NSCLC); MET exon 14 skipping mutation

Bayer’s Pharma Division Grows as Restructuring Drives Major Changes

4 weeks ago talkbio0Tagged Administration occupational activities, Bayer, DSO, Dynamic Shared Ownership, Kerendia, Neoplasms, Nubeqa, pharma division, restructuring, Sales growth, Xarelto

Bayer; pharma division; restructuring; job cuts; Dynamic Shared Ownership (DSO); sales growth; oncology; Kerendia; Nubeqa; Xarelto; management changes